WebOct 11, 2024 · DiaMedica Therapeutics Inc: ClinicalTrials.gov Identifier: NCT04123613 Other Study ID Numbers: DM199-2024-001 : First Posted: October 11, 2024 Key Record Dates: Last Update Posted: March 31, 2024 Last Verified: March 2024 Individual Participant Data (IPD) Sharing Statement: ... WebThe Diamedica Baby CPAP is an oxygen concentrator driven continuous positive airway pressure system (CPAP) that does not require compressed gases. This product was selected for inclusion in WHO’s 2013 Compendium of Innovative Health Technologies for Low-Resource Settings. The Baby CPAP is primarily targeted for use in African countries.
DiaMedica Therapeutics, Inc. (DMAC)
WebMar 28, 2024 · 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota 55305 (Address of principal executive offices) (Zip Code) (763) 496-5454 (Registrant's telephone number, including area code) Not Applicable ... WebApr 11, 2024 · DiaMedica Therapeutics is committed to improving the lives of people suffering serious diseases with initial focus on acute ischemic stroke (AIS) and chronic … count how many clicks i can do
How Much Are DiaMedica Therapeutics Inc. (NASDAQ:DMAC) …
WebDec 1, 2024 · DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases. View Board of Directors Investor Contact Information Company DiaMedica Therapeutics, Inc. 301 Carlson … WebJan 3, 2024 · Mr. Pilnik DMAC stock SEC Form 4 insiders trading. Richard has made over 6 trades of the DiaMedica Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 35,000 units of DMAC stock worth $48,650 on 5 December 2024.. The largest trade he's ever made was buying 35,000 units of … WebOct 26, 2024 · MINNEAPOLIS-- ( BUSINESS WIRE )-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company has received further guidance from the U.S. Food and Drug Administration … count houses